Search

Displaying results 8661 - 8670 of 10000 in total
  1. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  2. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  3. Drug

    Rumex salicifolius var. mexicanus pollen

    go.drugbank.com/drugs/DB10902
    Approved

    Rumex salicifolius var. mexicanus pollen is mainly used in allergenic testing.

  4. Drug

    Salix lucida ssp. lasiandra pollen

    go.drugbank.com/drugs/DB10916
    Approved

    Salix lucida ssp. lasiandra pollen is mainly used in allergenic testing.

  5. Drug

    Sorghum bicolor subsp. bicolor pollen

    go.drugbank.com/drugs/DB10965
    Approved

    Sorghum bicolor subsp. bicolor pollen is mainly used in allergenic testing.

  6. Drug

    Sorghum bicolor subsp. drummondii pollen

    go.drugbank.com/drugs/DB10966
    Approved

    Sorghum bicolor subsp. drummondii pollen is mainly used in allergenic testing.

  7. Drug

    Poly(lactic acid)

    go.drugbank.com/drugs/DB15037
    ApprovedInvestigationalWithdrawn

    Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).

  8. Drug

    GS-9191

    go.drugbank.com/drugs/DB15084
    Investigational

    GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).

  9. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines.

  10. Drug

    ABX-PTH

    go.drugbank.com/drugs/DB05883
    Experimental

    ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.